An aluminum-induced increase in GFAP is attenuated by some chelators

Neurotoxicology and Teratology

Volumn 20, Issue 1, 1998, Pages 55-60

  Yokel, Robert A ^a   O'Callaghan, James P ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

3 Hydroxypyridin 4 ones; Aluminum; Desferrioxamine; Glial fibrillary acidic protein; Myelin basic protein; Neurofilament 68; Rabbit; Synaptophysin

Indexed keywords

3 HYDROXY 4 PYRIDONE DERIVATIVE; ALUMINUM; DEFEROXAMINE; DODECYL SULFATE SODIUM; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN INJURY; CHELATION; CONTROLLED STUDY; FRONTAL CORTEX; GLIOSIS; HIPPOCAMPUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROFILAMENT; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

ALUMINUM; ANIMALS; BRAIN CHEMISTRY; CEREBRAL CORTEX; CHELATING AGENTS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MYELIN BASIC PROTEINS; NEUROFILAMENT PROTEINS; RABBITS; SYNAPTOPHYSIN;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031939519     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(97)00069-X     Document Type: Article

References (41)

1. Allen D. D., Orvig C., Yokel R. A. Evidence for energy-dependent transport of aluminum out of brain extracellular fluid. Toxicology. 98:1995;31-39.
2. Beach T. G., Walker R., McGeer E. G. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia. 2:1989;420-436.
3. Brock T. O., O'Callaghan J. P. Quantitative changes in the synaptic vesicle proteins synapsin I and p38 and the astrocyte-specific protein glial fibrillary acidic protein are associated with chemical-induced injury to the rat central nervous system. J. Neurosci. 7:1987;931-942.
4. Burnette W. N. "Western blotting" Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A Anal. Biochem. 112:1981;195-203.
5. Cookson M. R., Pentreath V. W. Alterations in the glial fibrillary acidic protein content of primary astrocyte cultures for evaluation of glial cell toxicity. Toxicol In Vitro. 8:1994;351-359.
6. Crapper McLachlan D. R., Dalton A. J., Kruck T. P. A., Bell M. Y., Smith W. L., Kalow W., Andrews D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 337:1991;1304-1308.
7. Dang S., Rasmussen C. A., LeVine S. M. Immunocytochemical localization of desferrioxamine in the kidney, liver and brain of the developing and adult mouse. Implications for drug processing and therapeutic mechanisms Res. Commun. Mol. Pathol. Pharmacol. 86:1994;43-57.
8. Delacourte A. General and dramatic glial reaction in Alzheimer brains. Neurology. 40:1990;33-37.
9. Dobbin P. S., Hider R. C., Hall A. D., Taylor R. D., Sarpong P., Porter J. B., Xiao G., van der Helm D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones. Orally active iron chelators with clinical potential J. Med. Chem. 36:1993;2448-2458.
10. Flaten T. P., Alfrey A. C., Birchall J. D., Savory J., Yokel R. A. The status and future concerns of clinical and environmental aluminum toxicology. J. Toxicol. Environ. Health. 48:1996;527-542.
11. Fredenburg A. M., Sethi R. K., Allen D. D., Yokel R. A. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-, 1,2-diethyl-, and 1-[ethan-1′ol]-, 2-methyl 3-hydroxypyridin-4-one in the rat. Toxicology. 108:1996;191-199.
12. Genter M. B., Llorens J., O'Callaghan J. P., Peele D. B., Morgan K. T., Crofton K. M. Olfactory toxicity of β,β′-iminodipropionitrile in the rat. J. Pharmacol. Exp. Ther. 263:1992;1432-1439.
13. Hamos J. E., DeGennaro L. J., Drachman D. A. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 39:1989;355-361.
14. Hoeppner T. J., Morrell F. Control of scar formation in experimentally induced epilepsy. Exp. Neurol. 94:1986;519-536.
15. Huang Y., Savory J., Herman M. M., Nicholson J. R., Reyes J. C., Boyd J. C., Wills M. R. Quantitative evaluation of Al maltolate-induced neurodegeneration with subsequent Al removal by desferrioxamine treatment. Neurotoxicology. 16:1995;291-296.
16. Martin P. M., O'Callaghan J. P. Gene expression in astrocytes after neural injury. Aschner M., Kimmelberg H. K. The role of glia in neurotoxicity. 1996;285-310 CRC Press, Boca Raton, FL.
17. Llorens J., Crofton K. M., O'Callaghan J. P. Administration of 3,3′-iminodipropionitrile to the rat results in region-specific damage to the CNS at levels above the brain stem. J. Pharmacol. Exp. Ther. 265:1993;1492-1498.
18. McLachlan D. R. C. Aluminum and the risk for Alzheimer's disease. Environmetrics. 6:1995;233-275.
19. Norenberg M. D., Norenberg L. O. B., Cowman G. A., McCarthy M., Neary J. T. The effects of aluminum on astrocytes in primary culture. J. Neuropathol. Exp. Neurol. 48:1989;374.
20. Norton W. T., Aquino D. A., Hozumi I., Chiu F.-C., Brosnan C. F. Quantitative aspects of reactive gliosis. A review Neurochem. Res. 17:1992;877-885.
21. O'Callaghan J. P. Quantification of glial fibrillary acidic protein. Comparison of slot-immunobinding assays with a novel sandwich ELISA Neurotoxicol. Teratol. 13:1991;275-281.
22. O'Callaghan J. P. Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. Ann. NY Acad. Sci. 679:1993;195-210.
23. O'Callaghan J. P., Jensen K. F. Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. Neurotoxicology. 13:1992;113-122.
24. O'Callaghan J. P., Jensen K. F., Miller D. B. Quantitative aspects of drug and toxicant-induced astrogliosis. Neurochem. Int. 26:1995;115-124.
25. O'Callaghan J. P., Miller D. B., Reinhard J. F. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 521:1990;73-80.
26. O'Callaghan J. P., Miller D. B. Diethyldithiocarbamate increases distribution of cadmium to brain but prevents cadmium-induced neurotoxicity. Brain Res. 370:1986;354-358.
27. Panter S. S., McSwigan J. D., Sheppard J. R., Emory C. R., Frey W. H. Glial fibrillary acidic protein and Alzheimer's disease. Neurochem. Res. 10:1985;1567-1576.
28. Sajdel-Sulkowska E. M., Majocha R. E., Salim M., Zain S. B., Marotta C. A. The postmortem Alzheimer brain is a source of structurally and functionally intact astrocytic messenger RNA. J. Neurosci. Methods. 23:1988;173-179.
29. Savory J., Herman M. M., Erasmus R. T., Boyd J. C., Wills M. R. Partial reversal of aluminum-induced neurofibrillary degeneration by desferrioxamine in adult male rabbits. Neuropathol. Appl. Neurobiol. 20:1994;31-37.
30. Schwob V. S., Clar J. B., Agrawal D., Agrawal H. C. Electron microscopic immunocytochemical localization of myelin proteolipid protein and myelin basic protein to oligodendrocytes in rat brain during myelination. J. Neurochem. 45:1985;559-571.
31. Shaw G., Osborn M., Weber K. An immunofluorescence microscopical study of the neurofilament triplet proteins, vimentin and glial fibrillary acidic protein within the adult rat brain. Eur. J. Cell Biol. 26:1981;68-82.
32. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
33. Toimela T. A., Tahti H. Effects of mercury, methylmercury and aluminium on glial fibrillary acidic protein expression in rat cerebellar astrocyte cultures. Toxicol. In Vitro. 9:1995;317-325.
34. Yokel R. A. Aluminum chelation. Chemistry, clinical and experimental studies and the search for alternatives to desferrioxamine J. Toxicol. Environ. Health. 41:1994;131-174.
35. Yokel R. A., Melograna J. M. A safe method to acid digest small samples of biological tissues for graphite furnace atomic absorption analysis of aluminum. Biol. Trace Elem. Res. 5:1983;225-237.
36. Yokel R. A., McNamara P. J. Influence of renal impairment on aluminum kinetics. Bratter P, Schramel P. Trace element analytical chemistry in medicine and biology, vol. 5. 1989;331-336 de Gruyter, Berlin.
37. Yokel R. A., Lidums V., McNamara P. J., Ungerstedt U. Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate. A microdialysis study Toxicol. Appl. Pharmacol. 107:1991;153-163.
38. Yokel R. A., Datta A. K., Jackson E. G. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum. J. Pharmacol. Exp. Ther. 257:1991;100-106.
39. Yokel R. A., Fredenburg A. M., Meurer K. A., Skinner T. L. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab. Dispos. 23:1995;1178-1180.
40. Yokel R. A., Meurer K. A., Skinner T. L., Fredenburg A. M. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine. Drug Metab. Dispos. 24:1996;105-111.
41. Yokel R. A., Meurer K. A., Hong C. B., Dickey K. M., Skinner T. L., Fredenburg A. M. Short term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. Drug Metab. Dispos. 25:1997;182-190.